Siemens Healthcare and Varian Medical Systems today announced that clinicians at The Ohio State University are now using Varian software to plan and manage radiotherapy treatments delivered on a Siemens medical linear accelerator. The companies have developed and deployed an interface that connects Varian’s ARIA® oncology information system with Siemens’ ONCOR™ and PRIMUS™ accelerators and imaging systems.

The American Cancer Society celebrated the 100th anniversary of its founding in May.

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that its superDimension Electromagnetic Navigation Bronchoscopy (ENB™) system, the first technology of its kind, is included in the new American College of Chest Physicians (ACCP) guidelines to aid in diagnosing and managing lung cancer.  The evidence-based clinical practice guidelines were released by the ACCP earlier this month.

Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.

Researchers at Purdue University in West Lafayette, Ind., are working an imaging technology that combines atomic force microscopy and nuclear MR to simultaneously study the mechanical and biochemical behavior of cells.

Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.

Beaumont Hospital, Grosse Pointe has opened a new lung nodule clinic to provide early diagnosis and treatment of abnormal pulmonary nodules. Pulmonary nodules are a round or oval-shaped growth in the lung, sometimes referred to as a coin lesion or “spot” on the lung.

Exact Sciences has developed a stool-based screening test that detected 92 percent of cancers found on colonoscopy and 42 percent of precancerous polyps. The results fell shy of the company’s goal of a 50 percent polyp detection rate, according to an article in the New York Times; however, Exact Sciences indicated its plans to file for FDA approval of its Cologuard test.